Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(147 products)
- Bcr-Abl(103 products)
- EGFR(572 products)
- FAK(71 products)
- FLT(91 products)
- Fibroblast Growth Factor Receptor (FGFR)(169 products)
- JAK(246 products)
- PDGFR(126 products)
- RAAS(87 products)
- Src(80 products)
- Syk(37 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(262 products)
Show 6 more subcategories
Found 1522 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formula:C26H31N7O2Color and Shape:SolidMolecular weight:473.57EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Formula:C14H11BrN4O2SColor and Shape:SolidMolecular weight:379.23Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formula:C18H20F6N4OColor and Shape:SolidMolecular weight:422.37(3S,4R)-Tofacitinib
CAS:(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37VVD-118313
CAS:<p>VVD-118313 (5a) is a potent JAK1 inhibitor targeting allosteric cysteine, blocking cytokine signaling for cancer research.</p>Formula:C19H22Cl2N2O3SColor and Shape:SolidMolecular weight:429.36LT-850-166
<p>LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.</p>Formula:C30H29Cl2N7OColor and Shape:SolidMolecular weight:574.5lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468FGFR4-IN-10
<p>FGFR4-IN-10 (compound 5a) is a potent, selective FGFR4 inhibitor with IC50 of 70.7 nM, sparing FGFR1-3.</p>Formula:C20H19F3N6O3Color and Shape:SolidMolecular weight:448.4W23-1006
CAS:W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).Formula:C17H12BrN3O5Color and Shape:SolidMolecular weight:418.198Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formula:C32H31ClN6O4Color and Shape:SolidMolecular weight:599.08EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98FAK-IN-23
CAS:<p>FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).</p>Formula:C32H38F3N5O8Color and Shape:SolidMolecular weight:677.668HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formula:C26H32N8O3Color and Shape:SolidMolecular weight:504.58TGF-βRI inhibitor 3
CAS:<p>TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.</p>Formula:C21H21NO4Color and Shape:SolidMolecular weight:351.396BMS-066
CAS:BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.Formula:C19H21N7O2Purity:98%Color and Shape:SolidMolecular weight:379.42Tyrosine kinase-IN-9
CAS:<p>Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</p>Formula:C20H14ClN3O3Color and Shape:SolidMolecular weight:379.796FGFR3-IN-4
CAS:<p>FGFR3-IN-4 is a selective inhibitor targeting FGFR3, demonstrating an IC50 value of under 50 nM.</p>Formula:C26H24ClN7OColor and Shape:SolidMolecular weight:485.97TrxR/EGFR-IN-1
CAS:TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.Formula:C24H24AuClFN6O2PColor and Shape:SolidMolecular weight:710.878FGFR1 inhibitor-17
CAS:<p>FGFR1inhibitor-17 (Compound 92) is a potent inhibitor of FGFR1, with promising applications in cancer research.</p>Formula:C16H13ClN2O3Color and Shape:SolidMolecular weight:316.739TZEP7
CAS:<p>TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.</p>Formula:C27H19ClFNSColor and Shape:SolidMolecular weight:443.963
